Green light, or go slow: What FDA's new draft guidance means for social media in pharma

Click here to register 

Date: Thursday, March 13, 2014
Time: 2:00 PM ET / 11:00 AM PT

While not the last word on the subject, the agency's latest social media guidance was a good step forward. This informative webcast is designed to dissect the guidance and help brand directors and communication managers, whether currently engaging in social media or looking to do so, apply the rules now.

Experts from pharma marketing and digital media will leverage real scenarios to provide insights on the draft guidance, as the agency seeks to modernize its regulations for social and offer ways for pharma to communicate in the medium.

The event will explain the impact in the following areas:

-Handling of user-generated content

-Influence over third-party content

-New rules on submission of real-time content

-Responsibilities of those acting on the company's behalf

-Practicalities surrounding social media workflow

-Impact on expectations from consumers and HCPs

-What's next

Sponsored by: 

You must be a registered member of MMM to post a comment.

Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.

Email Newsletters